A 55-year-old woman with a 2-month history of recurrent tense bullae on the lower abdomen and inner thighs is suspected to have bullous pemphigoid. Skin biopsy shows subepidermal blister with eosinophilic infiltrate. To identify circulating IgG antibodies against specific BP antigens (BP180 and BP230) and assess disease activity, which investigation should be performed?

Explanation

## Serological Investigation for BP Antigen-Specific Antibodies **Key Point:** ELISA (enzyme-linked immunosorbent assay) for anti-BP180 and anti-BP230 antibodies is the most sensitive and specific serological test to detect circulating IgG antibodies against the specific bullous pemphigoid antigens and correlate with disease activity. ### Role of Serological Testing in BP While direct immunofluorescence is diagnostic, serological tests provide additional information: 1. **Detection of circulating antibodies** — confirms autoimmune nature 2. **Identification of antigen specificity** — BP180 vs. BP230 predominance 3. **Correlation with disease activity** — antibody titers may predict flares and guide therapy 4. **Prognostication** — anti-BP180 antibodies associated with more severe disease ### Comparison of Serological Methods | Method | Target | Sensitivity | Specificity | Clinical Application | |---|---|---|---|---| | **ELISA** | Anti-BP180/BP230 IgG | 90% | Very high | **Gold standard for serology**; prognostication | | Indirect IF (serum) | Circulating IgG at BMZ | 60–80% | Moderate | Supportive; less specific | | Immunoprecipitation | Antigen-antibody complexes | Moderate | Moderate | Research tool | | Immunoelectrophoresis | Serum protein fractions | Low | Low | Non-specific; not diagnostic | | Immunodiffusion | Antigen-antibody reactions | Low | Low | Outdated; rarely used | **High-Yield:** ELISA is superior to indirect immunofluorescence for serological diagnosis because it: - Directly targets the specific BP antigens (BP180 and BP230) - Provides quantitative antibody titers - Has higher sensitivity and specificity - Correlates with disease activity and prognosis ### Clinical Pearl **Anti-BP180 antibodies** are associated with: - More severe, generalized disease - Higher relapse rates - Worse prognosis **Anti-BP230 antibodies** are associated with: - Milder, localized disease - Better prognosis - Lower relapse rates This distinction helps guide treatment intensity and patient counseling. **Mnemonic:** **ELISA = Exact, Localized, Immunological Serology Analysis** — ELISA precisely identifies the specific BP antigens and quantifies antibody levels. ### When to Order ELISA in BP 1. **Seronegative BP** — when DIF is positive but indirect IF is negative 2. **Disease monitoring** — to assess response to therapy 3. **Prognostication** — anti-BP180 positivity predicts more severe disease 4. **Research and specialized centers** — for detailed antigen mapping [cite:Harrison 21e Ch 297]